{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:48Z","timestamp":1787732388907,"version":"build-2784847793"},"reference-count":101,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The registration of the tumour necrosis factor\u2010\u03b1 inhibitor adalimumab in 2015 was a major step forward in the treatment of hidradenitis suppurativa\/acne inversa (HS). However, it soon became evident that the effectiveness of adalimumab in daily practice was highly variable. A significant unmet medical need of HS patients remained, and the search for novel therapeutic targets was intensified. During the 10th European Hidradenitis Suppurativa Foundation (EHSF) e.V. Conference, reknown international HS investigators virtually presented and discussed the published data on these potential target molecules for future HS treatment. This article addresses the most promising molecules currently under investigation from a pathophysiological and clinical point of view. With phase III trials ongoing, the anti\u2010 interleukin (IL)\u201017 biologics bimekizumab and secukinumab are in the most advanced stage of clinical development showing promising results. In addition, targeting IL\u20101\u03b1 with bermekimab has shown encouraging results in two clinical trials. Directing treatment at neutrophil recruitment and activation by targeting IL\u201036 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending. In contrast to in situ evidence, Complement 5a (C5a) and C5a receptor blockade have only shown greater clinical benefit in patients with severe HS. Inhibition of Janus kinase (JAK) 1 signalling in HS showed clinical efficacy only in the highest dosage, highlighting that careful surveillance of the balance between safety and efficacy of JAK inhibition is warranted. Overall, clinical efficacies of all novel treatments reported so far are modest. To guide drug development, more and better\u2010defined translational data on the pathogenesis of this severe and enigmatic inflammatory skin disease are required.<\/jats:p>","DOI":"10.1111\/exd.14338","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T14:21:16Z","timestamp":1622816476000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Target molecules for future hidradenitis suppurativa treatment"],"prefix":"10.1111","volume":"30","author":[{"given":"Christos C.","family":"Zouboulis","sequence":"first","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Departments of Dermatology Venereology, Allergology and Immunology Dessau Medical Center Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[{"name":"Department of Dermatology Liverpool Hospital Sydney NSW Australia"},{"name":"University of New South Wales Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos\u2010Bourboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"4th Department of Internal Medicine Medical School National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B.E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Department of Dermatology Zealand University Hospital Roskilde Denmark"},{"name":"Institute of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Department of Dermatology H\u00f4pital Erasme Universite Libre de Bruxelles Bruxelles Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Nikolakis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Departments of Dermatology Venereology, Allergology and Immunology Dessau Medical Center Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Department of Dermatology NLSH University Hospital Bod\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Department of Dermatology and Institute of Medical Immunology\/Psoriasis Research and Treatment Center Charit\u00e9\u2010University Medicine Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V. Dessau Germany"},{"name":"Laboratory for Experimental Immunodermatology Erasmus University Medical Center Rotterdam Rotterdam The Netherlands"},{"name":"Department of Dermatology Erasmus University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14214"},{"key":"e_1_2_17_3_1","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?recrs=&cond=Hidradenitis+Suppurativa&term=&cntry=&state=&city=&dist=(website accessed March 4 2021)."},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17641"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18173"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16147"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16264"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16976"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19627"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48226-w"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00892"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17695"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.020"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.030"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024"},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14333"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903907"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033"},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13449"},{"key":"e_1_2_17_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18556"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15769"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.005"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17178"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00008"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00915.x"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14651"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.02.009"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-017-1769-5"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140712"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.12.4371-4380.2000"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400205"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.651"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5908"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000505184"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.019"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.10.010"},{"key":"e_1_2_17_44_1","unstructured":"A placebo\u2010controlled study of the safety of INCB054707 in participants with hidradenitis suppurativa (NCT03607487). ClinicalTrials.gov Website. Accessed July 31 2020."},{"key":"e_1_2_17_45_1","unstructured":"A study of oral upadacitinib tablet compared to placebo in adult participants with moderate to severe hidradenitis suppurativa to assess change in disease symptoms (NCT04430855).ClinicalTrials.gov(website accessed July 31 2020)."},{"key":"e_1_2_17_46_1","unstructured":"Topical ruxolitinib 1.5% for HS (NCT04414514).ClinicalTrials.gov(website accessed July 31 2020)."},{"key":"e_1_2_17_47_1","unstructured":"Tofacitinib for immune skin conditions in Down syndrome (NCT04246372).ClinicalTrials.gov(website accessed July 31 2020)."},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-018-0471-y"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0148fje"},{"key":"e_1_2_17_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19556"},{"key":"e_1_2_17_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15226"},{"key":"e_1_2_17_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932"},{"key":"e_1_2_17_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2010.12.005"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0724-8"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115835"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17426"},{"key":"e_1_2_17_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.09.009"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14056"},{"key":"e_1_2_17_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599417"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203672"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14036"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv361"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18877"},{"key":"e_1_2_17_64_1","article-title":"Complement split product C5a is elevated in moderate and severe hidradenitis suppurativa: clinical improvement by targeted therapy coming from the SHINE study","author":"Giamarellos\u2010Bourboulis EJ","year":"2021","journal-title":"Exp Dermatol"},{"key":"e_1_2_17_65_1","unstructured":"Global Newswire.ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS) 2020."},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9390-z"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.02.006"},{"key":"e_1_2_17_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031810"},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13922"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1800"},{"key":"e_1_2_17_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14894"},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101047"},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04668.x"},{"key":"e_1_2_17_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1592100"},{"key":"e_1_2_17_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00442-w"},{"key":"e_1_2_17_76_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4847812"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01236"},{"key":"e_1_2_17_78_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2013.1416"},{"key":"e_1_2_17_79_1","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0416"},{"key":"e_1_2_17_80_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1708"},{"key":"e_1_2_17_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-02018-4"},{"key":"e_1_2_17_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048"},{"key":"e_1_2_17_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.06926.x"},{"key":"e_1_2_17_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02737835"},{"key":"e_1_2_17_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-005-1386-1"},{"key":"e_1_2_17_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.046"},{"key":"e_1_2_17_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.113"},{"key":"e_1_2_17_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.09.002"},{"key":"e_1_2_17_89_1","doi-asserted-by":"publisher","DOI":"10.1159\/000028104"},{"key":"e_1_2_17_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2007.06.004"},{"key":"e_1_2_17_91_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.22.8702"},{"key":"e_1_2_17_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.10.008"},{"key":"e_1_2_17_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_17_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19795"},{"key":"e_1_2_17_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.11.018"},{"key":"e_1_2_17_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_2_17_97_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508787"},{"key":"e_1_2_17_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.011"},{"key":"e_1_2_17_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1221762"},{"key":"e_1_2_17_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_17_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_2_17_102_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503606"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/exd.14338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:19:16Z","timestamp":1693415956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":101,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/exd.14338"],"URL":"https:\/\/doi.org\/10.1111\/exd.14338","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2021-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}